Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies
Relapsed or Refractory Hematological Malignancies
DRUG: ENMD-2076
Define the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of oral daily ENMD 2076 by evaluation of adverse events, Day 1 through first cycle of therapy
Safety and toxicity of repeated oral dosing of ENMD 2076, Throughout study participation|Describe any preliminary evidence of anti-cancer effects of ENMD-2076 in patients with hematological malignancies, monthly
To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies